Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Grant Pollock

Urology Kenner, LA Medical Doctor

NPI 1740714302 CMS profile 3180691

200 W Esplanade Ave, Kenner, LA 70065

Open in the dashboard

General payments

$7,899

33 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Grant Pollock of Kenner, LA is reported in the CMS Open Payments database as having received $7,899 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,740 9
2023 General $272 6
2022 General $695 15
2021 General $70 2
2019 General $122 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Grant Pollock
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Grant Pollock were reported at $6,740. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Grant Pollock Urology median Middle half National median
2019 $122 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $70 $358 $111–$1,000 $132
2022 $695 $476 $143–$1,263 $149
2023 $272 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $6,740 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,526 24 payments
  2. PROCEPT BioRobotics Corporation $171 1 payment
  3. Coloplast Corp $65 1 payment
  4. Myriad Genetic Laboratories, Inc. $63 3 payments
  5. Janssen Biotech, Inc. $36 2 payments
  6. Urogen Pharma, Inc. $24 1 payment
  7. Pacira Pharmaceuticals Incorporated $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,400 4 payments
  2. Food and Beverage $1,340 28 payments
  3. Travel and Lodging $158 1 payment
Products named General payments · program years 2019–2025
  1. Lumenis Pulse 120H $6,558 5 payments
  2. General - BPH $264 6 payments
  3. LithoVue $232 5 payments
  4. AQUABEAM ROBOTIC SYSTEM $171 1 payment
  5. AMS $122 1 payment
  6. AccuMax $115 1 payment
  7. Moses $109 1 payment
  8. Titan $65 1 payment
  9. PROLARIS $63 3 payments
  10. GENERAL ERECTILE DYSFUNCTION $56 1 payment
  11. Other $143 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

485

Median for Urology: 1,053

Drug cost

$27,871

Median for Urology: $101,464

Branded share of claims

36.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 40 $23,251
Tamsulosin Hcl Generic 184 $1,804
Oxybutynin Chloride Er Oxybutynin Chloride Brand 121 $1,516
Finasteride Generic 69 $773
Bicalutamide Generic 14 $252
Ciprofloxacin Hcl Generic 27 $152
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $70
Meloxicam Generic 14 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$36,575

Medicare's payments for the services billed

Medicare patients

133

Average age 73

Services billed

323

23 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 44%
Diabetes 42%
Arthritis 40%
Chronic kidney disease 35%
Cancer 29%
Heart failure 28%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record